Search Results - "Handyside, Britta"
-
1
Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers
Published in Molecular therapy. Methods & clinical development (10-03-2022)“…Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus serotype 5 (AAV5)-based gene therapy vector containing a B-domain-deleted human…”
Get full text
Journal Article -
2
Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter
Published in Molecular therapy. Methods & clinical development (11-09-2020)“…Adeno-associated virus 5 (AAV5)-human factor VIII-SQ (hFVIII-SQ; valoctocogene roxaparvovec) is an AAV-mediated product under evaluation for treatment of…”
Get full text
Journal Article -
3
Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action
Published in Molecular therapy. Methods & clinical development (08-09-2022)“…Recombinant adeno-associated virus (AAV) is an effective platform for therapeutic gene transfer; however, tissue-tropism differences between species are a…”
Get full text
Journal Article -
4
Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood
Published in Molecular therapy. Methods & clinical development (08-09-2022)“…Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene transfer provided reduced bleeding for adult clinical trial participants with severe hemophilia A. However,…”
Get full text
Journal Article -
5
Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec
Published in Molecular therapy. Methods & clinical development (12-06-2020)“…AAV5-hFVIII-SQ (valoctocogene roxaparvovec) is an adeno-associated virus (AAV)-mediated gene therapy vector containing a B-domain-deleted human factor VIII…”
Get full text
Journal Article -
6
Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells
Published in Molecular therapy (07-12-2022)“…Recombinant adeno-associated virus (rAAV) vectors are often produced in HEK293 or Spodoptera frugiperda (Sf)-based cell lines. We compared expression profiles…”
Get full text
Journal Article -
7
-
8
Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice
Published in Molecular therapy (07-02-2018)“…Hemophilia A is an X-linked bleeding disorder caused by mutations in the gene encoding the factor VIII (FVIII) coagulation protein. Bleeding episodes in…”
Get full text
Journal Article -
9
A small molecule chaperone for alpha-1 antitrypsin deficiency-associated liver disease reduces liver polymer burden in the PiZ mouse model
Published in Journal of hepatology (01-07-2022)Get full text
Journal Article -
10
Abstract 12927: Impact of AAV- MYBPC3 Gene Transfer on Heart Structure and Function in Human and Mouse Models of Hypertrophic Cardiomyopathy
Published in Circulation (New York, N.Y.) (07-11-2023)“…Abstract only Background: Hypertrophic cardiomyopathy (HCM) is a life-threatening inherited heart disease characterized by left ventricular hypertrophy and…”
Get full text
Journal Article -
11
Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice
Published in The Journal of biological chemistry (25-09-2020)“…Autosomal recessive mutations in the galactosidase β1 (GLB1) gene cause lysosomal β-gal deficiency, resulting in accumulation of galactose-containing…”
Get full text
Journal Article -
12
Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency
Published in The Journal of biological chemistry (25-09-2020)“…Mutations in the galactosidase β 1 (GLB1) gene cause lysosomal β-galactosidase (β-Gal) deficiency and clinical onset of the neurodegenerative lysosomal storage…”
Get full text
Journal Article -
13
Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction
Published in The Journal of biological chemistry (01-12-2022)“…Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder caused by N-sulfoglucosamine sulfohydrolase (SGSH) deficiency. SGSH removes the…”
Get full text
Journal Article -
14
Correction: Intermittent enzyme replacement therapy prevents Neu1 deficiency
Published in The Journal of biological chemistry (13-11-2020)Get full text
Journal Article